Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPORT: Persistency of Response With or Without Xolair
NCT01125748Phase 4Completed
- Sponsor
- Genentech
- Start
- May 2010
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Genentech. Started May 2010; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01125748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125748.